Rhythm Pharmaceuticals, Inc. (NASDAQ: RGPX) reported that setmelanotide therapy produced robust, sustained and clinically significant weight loss in patients with acquired hypothalamic obesity at 2.5 years.
Alongside the long-term setmelanotide results, Rhythm reported that bivamelagon therapy achieved progressive reductions in body mass index and hunger measures in patients with acquired hypothalamic obesity at one year.
The data span two of the company's programs in acquired hypothalamic obesity, a condition the announcement abbreviated as acquired HO. The setmelanotide readout was framed around a 2.5-year time point, pointing to durability of effect over an extended follow-up period, while the bivamelagon data covered a one-year window and were tied to the 26-patient group. The characterizations of the weight-loss outcome as robust, sustained and clinically significant were the company's own, as stated in its disclosure.
Long-term efficacy data carry weight for a clinical-stage program because they speak to whether an initial treatment effect holds over time, a question central to the regulatory and commercial case for therapies aimed at chronic conditions.
By reporting sustained weight loss at 2.5 years for setmelanotide and progressive BMI and hunger reductions at one year for bivamelagon, Rhythm presented a dataset addressing both an established asset and a candidate at an earlier follow-up stage within the same indication. The company did not, in this disclosure, provide the magnitude of the weight-loss or BMI changes, statistical detail, or safety findings beyond the summary statements.
Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare genetic and acquired diseases that affect the melanocortin pathway, which regulates hunger and body weight. Its programs include setmelanotide and the investigational candidate bivamelagon, both of which it is studying in acquired hypothalamic obesity, a disorder marked by excessive hunger and weight gain.